Stay positive and happy. Work hard!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GM All !!
watchlist for nextweek! $ACGX, $AFOM, $CETX, $CYCA, $ENTB, $GHAV, $GRCU, $LLLI, $RGBP and $VPTK http://www.frontpagestocks.com/
$GRCU ~ The company’s management has been working on transitioning leadership and responsibilities for several weeks now, and in this time, Mr. Pitsicalis has developed a new strategy for 2018 with his team. In less than 90 days, the company will develop and launch a new blockchain technology platform to process payments in the cannabis space. In addition to this, the company will be releasing a new CBD-based product, which will be hitting shelves within 30 days. https://finance.yahoo.com/news/green-cures-botanical-distribution-inc-110000362.html?soc_src=social-sh&soc_trk=tw
$GHAV, $GRCU, $LLLI, $RGBP and $VPTK Put on radar, Ready to explode!
#Cemtrex $CETX Investing in Technology – How Category Growth is Changing the Game ?#CES #TechTrends #IoT #Wearables ?Read More>> ???? https://bit.ly/2mRFlQ3
Marijuana Stock $GRCU will be releasing a new CBD-based product, which will be hitting shelves within 30 days. https://finance.yahoo.com/news/green-cures-botanical-distribution-inc-110000362.html?soc_src=social-sh&soc_trk=tw
$RGBP medicinal chemistry program identified additional compounds that activate #NR2F6 #immunotherapy #cancer https://buff.ly/2DMjwtb
$RGBP Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company's contract research organization. https://www.prnewswire.com/news-releases/regen-biopharma-incs-medicinal-chemistry-program-has-identified-additional-compounds-that-activate-nr2f6-669711503.html?utm_content=buffer6dcba&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
$ACGX, $AFOM, $CETX, $CYCA, $ENTB, $GHAV, $GRCU, $LLLI, $RGBP and $VPTK Lotto Play!!!
$GRCU Huge News as The company will develop and launch a new blockchain technology platform to process payments in the cannabis space &plans to uplist by NEW Ceo. Read more:
$GRCU The company’s management has been working on transitioning leadership and responsibilities for several weeks now, and in this time, Mr. Pitsicalis has developed a new strategy for 2018 with his team. In less than 90 days, the company will develop and launch a new blockchain technology platform to process payments in the cannabis space. In addition to this, the company will be releasing a new CBD-based product, which will be hitting shelves within 30 days. https://finance.yahoo.com/news/green-cures-botanical-distribution-inc-110000362.html?soc_src=social-sh&soc_trk=tw
$GHAV Grand Havana Cuban Style Optimum Blend Whole Bean Coffee is a dark roasted blend of coffee beans hand selected from around the world. It is rich in flavor with a strong body and seductive aroma. #Cuban #Starbucks #Expresso @frontpagestocks http://www.frontpagestocks.com/grand-havana-coffee-inc-otcqb-ghav/
$ENTB Entest Biomedical Files 8K https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12472910 @frontpagestocks
$IVST OTCMarkets Quote https://www.otcmarkets.com/stock/IVST/quote
$RGBP Regen BioPharma Inc. (RGBP) and (RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company's contract research organization.
"We recently identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. In order to ensure that we capture as much intellectual property as possible, we screened a new 48,000 compound library containing diverse compounds," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "In doing so, we identified 25 new compounds that activate NR2F6. Remarkably, each newly-identified compound contained the key structure that we previously identified. This tells us that it is likely the key structural element we identified is an absolute requirement for activating NR2F6. We anticipate utilizing our three-dimensional x-ray crystallography program to attempt to provide a clear molecular picture of this recently identified element."
"This additional information supports our prior work in this area and gives us confidence we are indeed on the right path," says David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. "I am delighted that the agonist program is moving ahead in such a positive manner."
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (RGBP) and (RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
david.koos@regenbiopharma.com
http://www.regenbiopharma.com
On Radar $ACGX, $AFOM, $CETX, $CYCA, $ENTB, $GHAV, $GRCU, $LLLI, $RGBP and $VPTK
$RGBP Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6 @frontpagestocks http://www.stockonhighalert.net/2018/01/rgbp-regen-biopharma-incs-medicinal.html ....
#IVST Innovest Global, Inc. Continues Diversification Into High-Growth Businesses, Beginning Revenue Growth Generation - Spotlight Growth https://www.cnbc.com/2018/01/11/globe-newswire-innovest-global-inc-continues-diversification-into-high-growth-businesses-beginning-revenue-growth-generation--spotlight.html
$LLLI Consolidating for the next leg up. $LLLI #Trending LAMPERD LESS LETHAL, INC. (OTC PINK: LLLI) Protection, Safety, Law Enforcement and Investment! The Time Has Come For $LLLI News article #LessLethal #cops #police Trump
https://ow.ly/zS4L30hJXu8 @Lamperd_LLLI @LLLI_LessLethal
$GRCU company will be releasing a new CBD-based product, which will be hitting shelves within 30 days. https://finance.yahoo.com/news/green-cures-botanical-distribution-inc-110000362.html
$GRCU The company’s management has been working on transitioning leadership and responsibilities for several weeks now, and in this time, Mr. Pitsicalis has developed a new strategy for 2018 with his team.
$IVST Back on Radar!
$CETX Looking good today!!
$GRCU Green Cures and Botanical Distribution Inc. (OTC PINK: GRCU), an innovative hemp-infused nutrition, botanical, sports, and body care products company, as previously announced, Green Cures has appointed Mr. William Pitsicalis as the new Chief Executive Officer (CEO). Effective today, Mr. Joseph Tragesser has resigned as CEO, allowing Mr. Pitsicalis to begin leading the company moving forward. https://finance.yahoo.com/news/green-cures-botanical-distribution-inc-110000362.html?soc_src=social-sh&soc_trk=tw
Watchlist Ready to Breakout! $ACGX, $AFOM, $CETX, $CYCA, $ENTB, $GHAV, $GRCU, $LLLI, $RGBP and $VPTK
$CETX @2.97+0.35 (+13.36%)
$RGBP Regen BioPharma, Inc.’s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6 @frontpagestocks https://finance.yahoo.com/news/regen-biopharma-inc-medicinal-chemistry-130000526.html
$RGBP recently identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. In order to ensure that we capture as much intellectual property as possible, we screened a new 48,000 compound library containing diverse compounds," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "In doing so, we identified 25 new compounds that activate NR2F6. Remarkably, each newly-identified compound contained the key structure that we previously identified. This tells us that it is likely the key structural element we identified is an absolute requirement for activating NR2F6. We anticipate utilizing our three-dimensional x-ray crystallography program to attempt to provide a clear molecular picture of this recently identified element. http://www.stockonhighalert.net/2018/01/rgbp-regen-biopharma-incs-medicinal.html
$ACGX on watch !!
$RGBP News is out!!
The company is rapidly expanding the number of activating compounds in its portfolio
SAN DIEGO, January 17, 2018 /PRNewswire/ --
Regen BioPharma Inc. (RGBP) and (RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company's contract research organization. http://www.stockonhighalert.net/2018/01/rgbp-regen-biopharma-incs-medicinal.html
$RGBP News!! Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6 http://www.stockonhighalert.net/2018/01/rgbp-regen-biopharma-incs-medicinal.html
$AFOM All For One Media Corp. SEC Filing: Form 10-K
$RGBP "We recently identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. In order to ensure that we capture as much intellectual property as possible, we screened a new 48,000 compound library containing diverse compounds," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "In doing so, we identified 25 new compounds that activate NR2F6. Remarkably, each newly-identified compound contained the key structure that we previously identified. This tells us that it is likely the key structural element we identified is an absolute requirement for activating NR2F6. We anticipate utilizing our three-dimensional x-ray crystallography program to attempt to provide a clear molecular picture of this recently identified element." http://www.stockonhighalert.net/2018/01/rgbp-regen-biopharma-incs-medicinal.html
On Radar: $IVST Innovest Global, Inc. is a diversified holding company that focuses on acquiring niche, high-growth businesses that are capable of generating significant annual revenue. The company’s planned subsidiaries operate across telehealth, commercial energy, business-to-business distribution, and auto sales.
The report provides an overview of Innovest Global, Inc., its subsidiaries, financials, industry analysis and more. The content also covers the outlook of the high-growth telehealth and commercial energy industries, which the company operates within.
https://finance.yahoo.com/news/innovest-global-inc-continues-diversification-113000881.html
$RGBP Huge news out!!
Regen BioPharma Inc. (RGBP) and (RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company's contract research organization. http://www.stockonhighalert.net/2018/01/rgbp-regen-biopharma-incs-medicinal.html
$RGBP ~ continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. http://www.stockonhighalert.net/2018/01/rgbp-regen-biopharma-incs-medicinal.html
$RGBP News: SAN DIEGO, January 17, 2018 /PRNewswire/ --
Regen BioPharma Inc. (RGBP) and (RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company's contract research organization. http://www.stockonhighalert.net/2018/01/rgbp-regen-biopharma-incs-medicinal.html
$RGBP Regen BioPharma Inc. (RGBP) and (RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company's contract research organization. http://www.stockonhighalert.net/2018/01/rgbp-regen-biopharma-incs-medicinal.html
$RGBP News is out!
$CETX Cemtrex, Inc. (CETX) Is At $2.62 Formed Wedge; Jericho Capital Asset Management LP Raised By $3.60 Million Its Truecar (TRUE) Stake https://heraldks.com/cemtrex-inc-cetx-is-at-2-62-formed-wedge-jericho-capital-asset-management-lp-raised-by-3-60-million-its-truecar-true-stake/
$RGBP is rapidly expanding the number of activating compounds in its portfolio http://www.stockonhighalert.net/2018/01/rgbp-regen-biopharma-incs-medicinal.html